Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

BACKGROUND AND AIMS: HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateos-Muñoz, Beatriz, Buti, María, Vázquez, Inmaculada Fernández, Conde, Marta Hernández, Bernal-Monterde, Vanesa, Díaz-Fontenla, Fernando, Morillas, Rosa María, García-Buey, Luisa, Badía, Ester, Miquel, Mireia, Amador-Navarrete, Alberto, Rodríguez-Tajes, Sergio, Ramos-Merino, Lucía, Madejón, Antonio, García-Retortillo, Montserrat, Arenas, Juan Ignacio, Cabezas, Joaquín, Santiago, Jesús Manuel González, Fernández-Rodríguez, Conrado, Cordero, Patricia, Diago, Moisés, Mancebo, Antonio, Pardo, Alberto, Rodríguez, Manuel, Hoyas, Elena, Moreno, Jose Javier, Turnes, Juan, Simón, Miguel Ángel, Marcos-Fosch, Cristina, Calleja, Jose Luis, Bañares, Rafael, Lens, Sabela, Garcia-Samaniego, Javier, Crespo, Javier, Romero-Gomez, Manuel, Gea, Francisco, de Santiago, Enrique Rodríguez, Moreno, Santiago, Albillos, Agustin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897881/
https://www.ncbi.nlm.nih.gov/pubmed/36737575
http://dx.doi.org/10.1007/s10620-022-07817-w
Descripción
Sumario:BACKGROUND AND AIMS: HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). METHODS: Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19. RESULTS: Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04–0.67, p = 0.01). CONCLUSION: Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10620-022-07817-w.

Ejemplares similares